RPL17 and melorheostosis: Patients (pts) with advanced inoperable melanoma (MEL), cutaneous/head and neck squamous cell or adenoid cystic carcinoma (cSCC, SCCHN, ACC) are eligible for single agent CV8102, MEL and SCCHN pts without response after 12 weeks of anti-PD1 treatment are eligible for the combination part.Pts are treated with up to 8 IT injections of CV8102 into a single tumor lesion over a 12 week period.